Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

DNL126

PreclinicalSmall molecule

DDenali Therapeutics Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mucopolysaccharidosis Type IIIAActive, not recruiting

Mucopolysaccharidosis Type IIIAPreclinical

Active, not recruiting

Timeline

Expected Milestones

Q3 2028

PreclinicalActive, not recruiting

Mucopolysaccharidosis Type IIIA

NCT06181136

Clinical

Trials by Indication[1]

Mucopolysaccharidosis Type IIIA1 trial

A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)

Active, not recruiting·DDenali Therapeutics Inc.·Preclinical·NCT06181136·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DNL126. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DNL126 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DNL126. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Denali Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DDenali Therapeutics Inc.

Related News